Teva share price hits nearly 10-year high

The Israeli pharmaceutical company’s stock has risen 20% over the past month.

The share price of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) hit a high of nearly 10 years last week. The Israeli pharmaceutical company’s share price closed up 1.44% on Friday, giving a market cap of $43.512 billion, having been slightly higher earlier in the week on Wednesday before falling back. Israel's most valuable company has not been trading so high since early 2017.

RELATED ARTICLES

The dual traded company, led by CEO Richard Francis, has issued several positive reports in recent weeks, helping the stock recover from a period of weakness and leading to a rise of about 20% in the past month.

In late July, the company released positive second quarter financial results and raised its annual revenue guidance. This month, the pharmaceutical company reported that Moody's had upgraded Teva's debt rating to investment grade, after Fitch had done so earlier this year. Another positive report from last week was that the US Food and Drug Administration (FDA) has accepted Teva's application for approval of the drug Ecopipam, for the treatment of children with Tourette's syndrome. The review process will be an accelerated process and the target date for the decision is the end of the first quarter of 2027.

As of today, according to "The Wall Street Journal," there are 13 analysts covering Teva's stock, of which 12 have positive recommendations and one is neutral. Their average price target is $42.38, reflecting a 12.3% premium to the current price on the New York Stock Exchange.

Published by Globes, Israel business news - en.globes.co.il - on August 23, 2026.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2026.